Pharma Pulse 11/19/24: Behind FDA PD-1 Inhibitor Label Restrictions, Email Reminders Improve Flu Shot Rates & more

Rationale Behind the Recent FDA PD-1 Inhibitor Label Restrictions
Ron Lanton, Partner, Lanton Law, discusses why the regulatory body made the decision to place restrictions on PD-1 inhibitors for gastric cancers.

AHA 2024: Email Reminders Improve Flu Shot Rates, Particularly Among Heart Attack Survivors
The encouraging results suggest this low-cost, scalable strategy should be considered for population-level outreach globally to improve flu vaccination rates.

Eli Lilly and Novo Want to Shake off Ozempic Copycats. Are They Ready to Meet Demand?
Makers of Ozempic, Zepbound fight to stop compounded copies of their drugs; unclear whether pharmaceutical companies can increase production enough.

Hims & Hers Appoints Tenured Pharmaceutical, Regulatory, and Quality Experts to Key Leadership Positions
Hims & Hers Health, Inc. announced Deb Autor, former deputy commissioner at the FDA, will join the company’s board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality, and personalized for their needs.

Tinu Cherian Abraham on LinkedIn
Pharmaceutical Commerce Magazine : 'Analyzing Branded and Generic Pharmaceuticals'

In a video interview with Pharma Commerce, Jonathan Colehower, managing director, global operations & supply chain practice at UST, discussed with Editor Nicholas Saraceno on how the East and Gulf Coast port strikes highlighted the contrasting dynamics between branded and generic pharmaceuticals. Branded drugs, which offer higher profit margins, are produced at limited manufacturing sites, creating potential vulnerabilities. In contrast, generics have multiple supply sources but operate with tighter margins, leading to less robust business controls and raising concerns about safety. This disparity underscores the complex challenges faced by both sectors in the pharmaceutical industry. Colehower also spoke on the valuable in pharma supply chain transparency and visibility.

Watch the video interview and transcript here https://lnkd.in/gJHy8MCX

Krishna Sudheendra Manu Gopinath Alexander Varghese Leslie Schultz Vijay Padmanabhan Sunil Balakrishnan Niranjan Ramsunder Tony Velleca Praveen Prabhakaran Sajesh Gopinath Yuval Wollman Colleen Doherty Kavita Kurup Krishna Kishore Ankarboina David Berney Krishna Prasad Youssef Mogadam Vivianne Farmer Vinay Kumar Vijayakumar Neha Misri Merrick Laravea Roshni Das Kailash Attal Kaushal Tripathi

#UST #PublicRelations #MediaRelations #PR #CorporateCommunications

Have news you want us to share in Pharma Pulse? Reach out to Social Media Editor Miranda Schmalfuhs